- Human（2）
No data
- His Tag（1）
- His Tag & Avi Tag（1）
No data
- HEK293（2）
No data
- Biotin-labeled（1）
- Unconjugated（1）
No data
- RUO（2）
No data
- No（2）
No data
- 25ug/$335.00
- 200ug/$2180.00
No data
- 25ug/$125.00
- 200ug/$700.00
No data
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-G & B2M & Peptide (RIIPRHLQL) | Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein (MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $335.00 25ug | |||
| HLA-G & B2M & Peptide (RIIPRHLQL) | Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Osugacestat | AL-101(BMS); BMS-906024 | Phase 2 Clinical | Bristol-Myers Squibb Company, Glaxosmithkline Plc | Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
